Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Inflammopharmacology

Volumn 23, Issue 5, 2015, Pages 231-269

  Rainsford, K D ^a   Parke, Ann L ^b   Clifford Rashotte, Matthew ^c   Kean, W F ^c  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Chloroquine; Chronic inflammation; Cytokine; Dermatological; Hydroxychloroquine; Inflammasome; Lupus; Lysosomotropic activity; Rheumatoid arthritis; Sj gren s syndrome; Toll like receptors

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIPARASITIC AGENT; ARACHIDONIC ACID; CHLOROQUINE; HYDROXYCHLOROQUINE; IMIPRAMINE; INTERLEUKIN 1; MELANIN; PHOSPHOLIPID ANTIBODY; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; AREA UNDER THE CURVE; ATHEROSCLEROSIS; AUTOPHAGOSOME; B LYMPHOCYTE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARTILAGE; CARTILAGE DEGENERATION; CELLULAR IMMUNITY; CHONDROLYSIS; CYTOKINE PRODUCTION; DIASTEREOISOMER; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ELIMINATION HALF-LIFE; EX VIVO STUDY; EYE INJURY; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; LEUKOCYTE; LYSOSOME; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PHAGOCYTE; PHARMACODYNAMICS; PHOSPHOINOSITIDE METABOLISM; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; RENAL CLEARANCE; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VOLUME OF DISTRIBUTION; ANIMAL; ARTHRITIS, RHEUMATOID; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 84941874455     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-015-0239-y     Document Type: Review

References (388)

1. Abdel-Hamid H, Oddis CV, Lacomis D (2008) Severe hydroxychloroquine myopathy. Muscle Nerve 38:1206–1210
2. Abou-Raya S et al. (2014) Efficacy of hydroxychloroquine in the treatment of symptomatic knee osteoarthritis in older adults: a randomized placebo-controlled trial. Ann Rheum Dis 73:756–757
3. Acha-Orbea H, Groscurth P, Lang R, Stitz J, Hengartner H (1983) Characterization of cloned cytotoxic lymphocytes with NK-like activity. J Immunol 130:2952–2959
4. Achuthan S, Ahluwalia J, Shafig N, Pareek A, Chandurkar N, Malhotra S (2015) Hydroxychloroquine’s efficacy as an antiplatelet agent study in healthy volunteers: a proof of concept study. J Cardiovasc Pharmacol Ther 20:174–180
5. Ackerman NR, Jubb S, Marlowe SL (1981) Effects of various anti-inflammatory and anti-rheumatic agents on the synthesis, secretion and activity of a cartilage proteoglycan-degrading enzyme and other macrophage enzymes. Biochem Pharmacol 30:2147–2155
6. Adams EM, Yocum DE, Bell CL (1983) Hydroxychloroquine in the treatment of rheumatoid arthritis. Am J Med 75:321–326
7. Adedoyin A, Frye RF, Mauro K, Branch RA (1998) Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. Br J Clin Pharmacol 46:215–219
8. Aderounmu AF, Fleckstein L (1983) Pharmacokinetics of chloroquine diphosphate in the dog. J Pharmacol Exp Ther 1983(223):633–639
9. Adeyemi EO, Chadwick VS, Hodgson HJ (1990) The effect of some anti-inflammatory agents on elastase release from neutrophils in vitro. J Pharm Pharmacol 42:487–490
10. Adjepon-Yamoah KK, Woolhouse NM, Prescott LF (1986) The effect of chloroquine on paracetamol disposition and kinetics. Br J Clin Pharmacol 21:322–324
11. Akintonwa A, Gbajumo SA, Mabadeje AF (1988) Placental and milk transfer of chloroquine in humans. Ther Drug Monit 10:147–149
12. Ali HM (1985) Reduced ampicillin bioavailability following oral coadministration with chloroquine. J Antimicrob Chemother 15:781–784
13. Alisky JM, Chertkova EL, Iczkowski KA (2006) Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. Med Hypotheses 67:1090–1094
14. Andreas K, Haupl T, Lubke C, Ringe J, Morawietz L, Wachtel A, Sittinger M, Kaps C (2009) Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther 11:R15
15. Antoine JC, Goud B, Jouanne C, Maurice M, Feldmann G (1985) Ammonium chloride, methylamine and chloroquine reversibly inhibit antibody secretion by plasma cells. Cell Biol 55:41–54
16. Arner EC, Darnell LR, Pratta MA, Newton RC, Ackerman NR, Galbraith W (1987) Effect of antiinflammatory drugs on human interleukin-1-induced cartilage degradation. Agents Actions 21:334–336
17. Ashraf T, Jiang W, Hogue MT, Henderson J, Wu C, Bendayan R (2014) Role of anti-inflammatory compounds in human immunodeficiency virus-1 glycoprotein120-mediated brain inflammation. J Neuroinflamm 11:11. doi:10.1186/1742-2094-11
18. Ausiello CM, Barbieri P, Spagnoli GC, Ciompi ML, Casciani CU (1986) In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients. Clin Exp Rheumatol 4:255–259
19. 2 activity by chloroquine and mepacrine. J Pharm Pharmacol 34:736–738
20. Avina-Zubieta JA, Galindo-Rodriguez G, Newman S, Suarez-Almazor ME, Russell AS (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 57:582–587
21. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J (1996) Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 30:194–210
22. Barbieri P, Ausiello C, Spagnoli GC, Qintieri F, Ciompi ML (1985) Chloroquine treatment induces decrease of spontaneous and interferon enhanced NK activity in rheumatoid arthritis. Int J Immunother 1:211–214
23. Bartholomew JS, Lowther DA (1987) Receptor-mediated binding of leukocyte elastase by chondrocytes. Arthritis Rheum 30:431–438
24. Baum J (1983) Treatment of juvenile arthritis. Am Fam Physician 27:133–139
25. Bellamy N, Brooks PM (1986) Current practice in antimalarial drug prescribing in rheumatoid arthritis. J Rheumatol 13:551–555
26. Ben-Chetrit E, Fischel R, Hinz B, Levy M (2005) The effects of cochicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-1. Rheumatol Int 25:332–335
27. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42:145–153
28. Bergqvist Y, Hed C, Funding L, Suther A (1985) Determination of chloroquine and its metabolites in urine: a field method based on ion-pair extraction. Bull WHO 63:893–898
29. Biasi D, Caramaschi P, Carletto A, Pacor ML, Bambara LM (2000) Combination therapy with hydroxychloroquine, gold sodium thiomalate and methotrexate in early rheumatoid arthritis. An open 3-year study. Clin Rheumatol 19:505–507
30. Blackham A, Radziwonik H, Shaw IH (1975) The Arthus reaction in guinea-pig knee joints. A test for anti-inflammatory drugs. Agents Actions 5:519–527
31. Boelaert JR, Piette J, Sperber K (2001a) The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 20:137–140
32. Boelaert JR, Yaro S, Augustijns P, Meda N, Schneider YJ, Schols D, Mols R, De Laere EA, Van de Perre P (2001b) Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. AIDS 15:2205–2207
33. Bonfante H et al. (2008) Assessment of the use of hydroxychloroquine on knees’ osteoarthritis treatment. Rev Bras Rheumatol 48:208–212
34. Borden MB, Parke AL (2001) Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf 24:1055–1063
35. Boström H, Moretti A, Whitehouse M (1963) Studies of the biochemistry of heart valves. On the biosynthesis of mucopolysaccharides in bovine heart valves. Biochem Biophys Acta 74:213–221
36. 35S metabolism in vivo. Biochem Pharmacol 13:413–420
37. 1 cells with 17D yellow fever virus: effects of chloroquine and cytochalasin B. J Gen Virol 65:791–794
38. Brennan FR, Negroiu G, Buzás EI, Fülöp C, Holló K, Mikecz K, Glant TT (1995) Presentation of cartilage proteoglycan to a T cell hybridoma derived from a mouse with proteoglycan-induced arthritis. Clin Exp Immunol 100:104–110
39. Bretano F, Schorr O, Gay RE, Gay S, Kyburz D (2005) RNA released from necrotic synovial fluid in RA—evidence of an inhibitory effect on toll-like receptor signalling. Arthritis Rheum 52:2656–2665
40. British National Formulary 57 (2009) BMJ Group and RPS Publishing, London, p 566
41. Brocks DR, Mehvar R (2003) Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 42:1359–1382
42. Brocks DR, Pasutto FM, Jamali F (1992) Analytical and semi-preparative high-performance liquid chromatographic separation and assay of hydroxychloroquine enantiomers. J Chromatogr 581:83–92
43. Brown ND, Poon BT, Chulay JD (1985) Chloroquine metabolism in man: urinary excretion of 7-chloro-4-hydroxy-quinoline and 7-chloro-4-aminoquinoline metabolites. J Chromatogr 345:209–214
44. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, Muscarà M, Vignati G, Stramba-Badiale M, Catelli L, Lojacono A, Cavazzana I, Ghirardello A, Vescovi F, Gambari PF, Doria A, Meroni PL, Tincani A (2001) Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counter-immunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 44:1832–1835
45. Bryant LR et al. (1995) Hydroxychloroquine in the treatment of erosive osteoarthritis. J Rheumatol 22:1527–1531
46. Bygbjerg IC, Theander TG, Andersen BJ, Flachs H, Jepsen S, Larsen PB (1986) In vitro effect of chloroquine, mefloquine and quinine on human lymphocyte proliferative responses to malaria antigens and other antigens/mitogens. Trop Med Parasit 37:245–247
47. Bygbjerg IC, Svenson M, Theander TG, Bendtzen K (1987) Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes. Int J Immunopharmacol 9:513–519
48. Cameron MC, Word AP, Dominguez A (2014) Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. Dermatol Online J 20 (pii: 13030/qt1q90q0h5)
49. Canadian Rheumatology Association (2000) Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 27:2919–2921
50. Cankaya H, Alpöz E, Karabulut G, Güneri P, Boyacioglu H, Kabasakal Y (2010) Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110:62–67
51. Cansu DU, Korkmaz C (2008) Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford) 47:378–379
52. Carmichael SJ, Beal J, Day RO, Tett SE (2002) Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 29:2077–2083
53. Carmichael SJ, Charles B, Tett SE (2003) Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 25:671–681
54. Carmichael SJ, Day RO, Tett SE (2013) A cross-ectional survey of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. Intern Med J 43:547–553
55. Cecchi E, Porzio F (1964) Affinité de l-hydroxychloroquine pour les tissues articulaires. Rhumatologie 16:399–400
56. Cervera R, Khamashta MA, Hughes GR (2009) The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 18:869–874
57. Chafin CB, Regna NL, Hammanod SE, Reilly CM (2013) Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine and prednisone treatment. Int Immunopharmacol 17:894–906
58. Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, Sperber K (1996) Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 18:1080–1092
59. Choi HK, Seeger JD, Kuntz KM (2000) A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 43:2316–2327
60. Churchill FC, Mount DL, Schwartz IK (1983) Determination of chloroquine and its major metabolite in blood using perfluoroacylation followed by fused-silica capillary gas chromatography with nitrogen-sensitive detection. J Chromatogr 274:111–120
61. Clarke AK (1998) Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 37:580
62. Clarke AK, Vernon-Roberts B, Currey HLF (1975) Assessment of anti-inflammatory drugs in the rat using subcutaneous implants of polyurethane foam impregnated with dead tubercule bacilli. Ann Rheum Dis 34:326–331
63. Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, Wall B, Wallace DJ, Bell CL, Sleckman J (1997) Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 24:1896–1902
64. Colombo C, Butler M, Hickman L, Selwyn M, Chart J, Steinetz B (1983) A new model of osteoarthritis in rabbits. II. Evaluation of anti-osteoarthritic effects of selected antirheumatic drugs administered systemically. Arthritis Rheum 26:1132–1139
65. Combe B, Guttierrez M, Anaya JM, Sany J (1993) Possible efficacy of hydroxychloroquine on accelerated nodulosis during methotrexate therapy for rheumatoid arthritis. J Rheumatol 20:755–756
66. Conaghan PG, Lehmann T, Brooks P (1997) Disease-modifying antirheumatic drugs. Curr Opin Rheumatol 9:183–190
67. Connolly KM, Stecher VJ, Danis E, Pruden DJ, LaBrie T (1988) Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs. Agents Actions 25:94–105
68. Cook JA, Randinitis EJ, Bramson CR, Wesche DL (2006) Lack of a pharmacokinetic interaction between azithromycin and chloroquine. Am J Trop Med Hyg 74:407–412
69. Costedoat-Chalumeau N, Amoura Z, Aymard G, Le TH, Wechsler B, Vauthier D, Dermer ME, Darbois Y, Piette JC (2002) Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 46:1123–1124
70. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48:3207–3211
71. Cowey FK, Whitehouse MW (1966) Biochemical properties of anti-inflammatory drugs. VII. Inhibition of proteolytic enzymes in connective tissue by chloroquine (resorchin) and related antimalarial antirheumatic drugs. Biochem Pharmacol 15:1071–1084
72. Cox A, Duff GW (1996) Cytokines as genetic modifying factors in immune and inflammatory diseases. J Pediatric Endocrinol Metab 9:129–132
73. Craig JC, Bhargava HN, Everhart ET, LaBelle B, Ohnsorge U, Webster RV (1988) Absolute configuration of the enantiomers of 7-chloro-4-[[4-diethylamino-1-methylbutyl]amino]quinoline (chloroquine). J Org Chem 53:1167–1170
74. Crossley MJ, Spowage M, Hunneyball IM (1987) Studies on the effects of pharmacological agents on antigen-induced arthritis in BALB/c mice. Drugs Exp Clin Res 13:273–277
75. Csuka M, Carrera GF, McCarty DJ (1986) Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study. JAMA 255:2315–2319
76. Cutler DJ (1993) Possible mechanisms of action of antimalarials in rheumatic disease. Agents Actions Suppl 44:139–143
77. Cutler DJ, MacIntyre AC, Tett SE (1988) Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl 24:142–157
78. Das SK, Pareek A, Mathur DS, Wanchu A, Srivastava R, Agarwal GG, Chauhan RS (2002) Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial—an Indian experience. Curr Med Res Opin 23:2227–2234
79. Das SK, Pareek A, Mathur DS, Wanchu A, Srivastava R, Agarwal GG, Chauhan RS (2007) Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial–an Indian experience. Curr Med Res Opin 23:2227–2234
80. Davila L, Ranganathan P (2011) Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol 7:537–550
81. Davis MJ, Woolf AD (1996) Role of antimalarials in rheumatoid arthritis–the British experience. Lupus 5(Suppl 1):S37–S40
82. Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM (2005) Hydroxychloroquine therapy in patients with primary Sjögren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology 44:449–455
83. Detert J, Klaus P, Listing J, Höhne-Zimmer V, Braun T, Wassenberg S, Rau R, Buttgereit F, Burmester GR (2014) Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial. Trials 15:412. doi:10.1186/1745-6215-15-412
84. De Duve C (1965) The separation and characterization of subcellular particles. Harvey Lect 59:49–87
85. de Oliveira AR, Cardoso CD, Bonato PS (2007) Stereoselective determination of hydroxychloroquine and its metabolites in human urine by liquid-phase microextraction and CE. Electrophoresis 28:1081–1091
86. Derksen RH, de Groot PG (2010) Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 19:470–474
87. Descloux E, Durieu I, Cochat P, Vital-Durand D, Ninet J, Fabien N, Cimaz R (2009) Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology 48:779–784
88. Dixon JS, Pickup ME, Bird HA, Lee MR (1981) Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis. Ann Rheum Dis 40:480–488
89. Dubois EL (1967) Management and prognosis of systemic lupus erythematosus. Bull Rheum Dis 18:477–482
90. Dubois EL (1978) Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 8:33–51
91. Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 31:257–274
92. Ducharme J, Fieger H, Ducharme MP, Khalil SK, Wainer IW (1995) Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol 40:127–133
93. Duve De, Wattiaux R, Wibo M (1962) Effects of fat-soluble compounds on lysosomes in vitro. Biochem Pharmacol 9:97–116
94. Easterbrook M (1990) Is corneal disposition of anti-malarials any indication of retinal toxicity? Can J Opthal 25:249–251
95. Easterbrook M (2002) Screening for antimalarial toxicity: current concepts. Can J Ophthalmol. 37:325–358 (331–334)
96. Edmead CE, Patel YI, Wilson A, Boulougouris G, Hall ND, Ward SG, Sansom DM (1996) Induction of activator protein (AP)-1 and nuclear factor-κB by CD28 stimulation involves both phosphoinositol-3-kinase and acidic sphingomyelinase signals. J Immunol 157:3290–3297
97. Edstein MD, Veenendaal JR, Newman K, Hyslop R (1986) Excretion of chloroquine, dapsone and pyrimethamine in human milk. Br J Clin Pharmacol 22:733–735
98. Edwards MH, Pierangeli S, Liu XW, Barker JH, Anderson G, Harris EN (1997) Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96:4380–4384
99. Eklund KK, Leirisalo-Repo M, Ranta P, Mäki T, Kautiainen H, Hannonen P, Korpela M, Hakala M, Järvinen P, Möttönen T (2007) Serum IL-1beta levels are associated with the presence of erosions in recent onset rheumatoid arthritis. Clin Exp Rheumatol 25:684–689
100. Emami J, Pasutto FM, Jamali F (1998) Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. Pharm Res 15:897–903
101. Emami J, Gerstein HC, Pasutto FM, Jamali F (1999a) Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol 77:118–123
102. Emami J, Pasutto FM, Mercer JR, Jamali F (1999b) Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sci 64:325–335
103. Estrada C, Gómez C, Martin C, Moncada S, González C (1992) Nitric oxide mediates tumor necrosis factor-α cytotoxicity in endothelial cells. Biochem Biophys Res Commun 186:475–482
104. Etherington DJ, Pugh D, Silver IA (1981) Collagen degradation in an experimental inflammatory lesion: studies on the role of the macrophage. Acta Biol Med Ger 40:1625–1636
105. Ette EI, Brorm-Awala EA, Essien EE (1987a) Effect of ranitidine on chloroquine disposition. Drug Intell Clin Pharm 21:732–734
106. Ette EI, Essien EE, Ogonor JI, Brown-Awala EA (1987b) Chloroquine in human milk. J Clin Pharmacol 27:499–502
107. Ette EI, Brown-Awala EA, Essien EE (1987c) Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 27:813–816
108. Evans D, Williamson WRN (1987) Chemistry of clinically active anti-inflammatory compounds. In: Williamson WRN (ed) Anti-inflammatory compounds. Marcel Dekker, New York, pp 193–302
109. Famaey JP, Fontaine J (1980) Prevention by chloroquine of hexosamine cartilage depletion by E-prostaglandins. Arthritis Rheum 23:780–781
110. Farrante A, Rowan-Kelly B, Seow WK, Thong YH (1986) Depression of human polymorphonuclear leucocyte function by anti-malarial drugs. Immunology 58:125–130
111. Finbloom DS, Silver K, Newsome DA, Gunkel R (1985) Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 12:692–694
112. Fosdyke DR (1975) Evidence for a relationship between chloroquine and complement from studies with lymphocyte mitogens: possible implications for the mechanism of chloroquine in disease. Can J Microbiol 21:1581–1586
113. Fox RI (1993) Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 23:82–91
114. Fox R (1996) Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5(Suppl 1):S4–S10
115. Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5(Suppl 1):S31–S36
116. French JK, Hurst NP, O’Donnell ML, Betts WH (1987) Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann Rheum Dis 46:42–45
117. Fryauff DJ, Richards AL, Baird JK, Richie TL, Mouzin E, Tjitra E, Sutamihardja MA, Ratiwayanto S, Hadiputranto H, Larasati RP, Pudjoprawoto N, Subianto B, Hoffman SL (1996) Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis. Antimicrob Agents Chemother 40:2737–2742
118. Fu S, Björkman A, Wåhlin B, Ofori-Adjei D, Ericsson O, Sjöqvist F (1986) In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum. Br J Clin Pharmacol 22:93–96
119. Fulkerson JP, Ladenbauer-Bellis IM, Chrisman OD (1979) In vitro hexosamine depletion of intact articular cartilage by E-prostaglandins: prevention by chloroquine. Arthritis Rheum 22:1117–1121
120. Furst DE (1993) Optimizing combination chemotherapy for rheumatoid arthritis. Ann N Y Acad Sci 696:285–291
121. Furst DE (1996) Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5(Suppl 1):S11–S15
122. Furst DE, Lindsley H, Baethge B, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D (1999) Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 42:357–365
123. Gallus AS (1979) Antiplatelet drugs: clinical pharmacology and therapeutic use. Drugs 18:439–477
124. Geamănu-Pancă A, Popa-Cheracheanu A, Marinescu B, Geamănu CD, Voinea LM (2014) Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review. J Med Life 7:322–326
125. Gendrel D, Verdier F, Richard-Lenoble D, Nardou M (1990) Interaction of cholestyramine and chloroquine. Arch Fr Pediatr 47:387–388
126. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB (2002) The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial. Diabetes Res Clin Pract 55:209–219
127. Gil JP, Gil Berglund E (2007) CYP2C8 and antimalarial drug efficacy. Pharmacogenomics 8:187–198
128. Ginsburg H, Geary TG (1987) Current concepts and new ideas on the mechanism of action of quinoline-containing antimalarials. Biochem Pharmacol 36:1567–1576
129. Girart MV, Fuertes MB, Domaica CI, Rossi LE, Zwirner NW (2007) Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol 179:3472–3479
130. Gladman DD, Blake R, Brubacher B, Farewell VT (1992) Chloroquine therapy in psoriatic arthritis. J Rheumatol 19:1724–1726
131. Glaumann H, Ahlberg J, Berkenstam A (1985) Rapid isolation of rat liver secondary lysosomes—autophagic vacuoles—following chloroquine administration. Exp Cell Res 163:151–158
132. Goekoop YP, Allaart CF, Breedveld FC, Dijkmans BA (2001) Combination therapy in rheumatoid arthritis. Curr Opin Rheumatol 13:177–183
133. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ (2000) Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 95:3460–3466
134. Gordon D, Lewis GP (1984) Effects of piroxicam on mononuclear cells. Comparison with other antiarthritic drugs. Inflammation 8(Suppl):S87–S102
135. Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zarnitsky C, Batouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 312:249–258
136. Gräbner R, Meerbach W (1983) Imipramine and chloroquine induce alterations in phospholipid content of rat lung. Exp Path 24:253–259
137. Grierson DJ (1997) Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 56:188–190
138. Gupta JD, Gruca M, Ablett W (1979) Effect of other drugs and chemicals on the degradation of aspirin in vitro: possible extrapolation to in vivo metabolism of aspirin. Eur J Drug Metab Pharmacokinet 4:103–108
139. Haberkorn A, Kraft HP, Blaschke G (1979) Antimalarial activity of the optical isomers of chloroquine diphosphate. Tropenmed Parasitol 30:308–312
140. Hage MP, Al-Badri MR, Azar ST (2014) A favourable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocronol Metab 5:77–85
141. Hanna B, Holdeman NR, Tang RA, Schiffman JS (2008) Retinal toxicity secondary to Plaquenil therapy. Optometry 79:90–94
142. Hedin U, Thyberg J (1985) Receptor-mediated endocytosis of immunoglobulin-coated colloidal gold particles in cultured mouse peritoneal macrophages. Chloroquine and monensin inhibit transfer of the ligand from endocytic vesicles to lysosomes. Eur J Cell Biology 39:130–135
143. Hereng T, Lambert M, Hachulla E, Samor M, Dubucquoi S, Caron C, Launay D, Morell-Dubois S, Queyrel V, Hatron PY (2008) Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 17:11–15
144. Hobbs HE, Sorsby A, Freeman A (1959) Retinopathy following chloroquine therapy. Lancet 2:478–480
145. Homewood CA, Warhurst DC, Peters W, Baggaly VC (1972) Lysosomes, pH and the anti-malarial action of chloroquine. Nature 235:50–52
146. Hostetler KY, Richman DD (1982) Studies on the mechanism of phospholipid storage induced by amantadine and chloroquine in Madin Darby canine kidney cells. Biochem Pharmacol 31:3795–3799
147. Hugosson E, Bjökman A, Troye-Blomberg M (2002) Chloroquine enhances the number of IL-10 producing cells and the expression of B7-2 and ICAM in in vitro-cultured PBMC. Scan J Immunol 55:399–402
148. Hunneyball IM, Crossley MJ, Spowage M (1986) Pharmacological studies of antigen-induced arthritis in BALB/c mice. II. The effects of second-line antirheumatic drugs and cytotoxic agents on the histopathological changes. Agents Actions 18:394–400
149. Hurst NP, French JK, Gorjatsschko L, Betts WH (1987) Studies on the mechanism of inhibition of chemotactic tripeptide stimulated human neutrophil polymorphonuclear leucocyte superoxide production by chloroquine and hydroxychloroquine. Ann Rheum Dis 46:750–756
150. Hurst NP, French JK, Gorjatschko L, Betts WH (1988) Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release. J Rheumatol 15:23–27
151. Hurvitz D, Hurschhorn K (1965) Suppression of in vitro lymphocyte responses by chloroquine. New Engl J Med 273:23–26
152. Ignarro LJ (1971) Dissimilar effects of anti-inflammatory drugs on stability of lysosomes from peritoneal and circulating leukocytes and liver. Biochem Pharmacol 20:2861–2870
153. Ignarro LJ (1974) Release of neutral protease and beta-glucuronidase from human neutrophils in the presence of cartilage treated with various immunologic reactants. J Immunol 113:298–308
154. Ignarro LJ, Colombo C (1972) Enzyme release from guinea-pig polymorphonuclear leucocyte lysosomes inhibited in vitro by anti-inflammatory drugs. Nat New Biol 239:155–157
155. Ilo EC, Orisakwe OE, Ilondu NA, Okwoli N, Brown SA, Elo-Ilo J, Agbasi PU (2006) Effect of chloroquine on the bioavailability of ciprofloxacin in man. J Control Release 116:e109–e110
156. Ilo CE, Ezejiofor NA, Agbakoba N, Brown SA, Maduagwuna CA, Agbasi PU, Orisakwe OE (2008) Effect of chloroquine on the urinary excretion of ciprofloxacin. Am J Ther 15:419–422
157. Iredale J, Fieger H, Wainer IW (1993) Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine. Semin Arthritis Rheum 23:74–81
158. Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD, Salmon JE, Buyon JP (2010) Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 69:1827–1830
159. Jang C-H, Choi J-H, Byun M-S, Jue D-M (2006) Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 45:703–710
160. Järvinen K, Vuolteenaho K, Nieminen R, Moilanen T, Knowles RG, Moilanen E (2008) Selective iNOS inhibitor 1400 W enhances anti-catabolic IL-10 and reduces destructive MMP-10 in OA cartilage. Survey of the effects of 1400 W on inflammatory mediators produced by OA cartilage as etected by protein antibody array. Clin Exp Rheumatol 26:275–282
161. Jarzyna R, Kiersztan A, Lisowa O, Bryła J (2001) The inhibition of gluconeogenesis by chloroquine contributes to its hypoglycaemic action. Eur J Pharmacol 428:381–388
162. Jokar M et al. (2013) The effect of hydroxychloroquine on symptoms of knee osteoarthritis: a double-blind randomized controlled clinical trial. Iran J Med Sci 38(3):221–226
163. Jones CJP, Jayson MIV (1984) Chloroquine: its effect on leucocyte auto- and heterophagocytosis. Ann Rheum Dis 43:205–212
164. Jones CJP, Salisbury RS, Jayson MIV (1984) The presence of abnormal lysosomes in lymphocytes and neutrophils during chloroquine therapy: a quantitative ultrastructural study. Ann Rheum Dis 43:710–715
165. Jover JA, Leon L, Pato E, Loza E, Rosales Z, Matias MA, Mendez-Fernandez R, Díaz-Valle D, Benitez-Del-Castillo JM, Abasolo L (2012) Long-term use of antimalarial drugs in rheumatic diseases. Clin Exp Rheumatol 30:380–387
166. Julkunen H, Rokkanen P, Laine H (1976) Chloroquine treatment and bone changes in rheumatoid arthritis. Scand J Rheumatol 5:36–38
167. Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, Lou W, Fortin PR (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62:863–868
168. Kalmanson GM, Guze LB (1963) Effects of hydroxyl-chloroquine on immune mechanisms. Clin Res 11:106
169. Kamal M, Bassiouni M (1992) Chloroquine inhibits elastase enzyme activity in vitro. Clin Exp Rheumatol 10:99–104
170. Kamal MA, Jusko WJ (2004) Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays. J Clin Pharmacol 44:1034–1045
171. 2-microglobulin from human platelets by chloroquine diphosphate. Transfusion 28:14–17
172. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, Richardson BC (2002) The apoptotic ligands, TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 169:6020–6029
173. Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W (1998) Chloroquine inhibits roinflammatory cytokine release into human whole blood. Am J Physiol 274:R1058–R1064
174. Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68:1105–1112
175. Katz SJ, Russell AS (2011) Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 23:278–281
176. Kelman SM, Sullivan SG, Stern A (1981) Chloroquine- and primaquiine-induced alterations of glucose metabolism in the uninfected red cell. Biochem Pharmacol 30:81–87
177. Kheirkhah A, Amoli FA, Azari AA, Molaei S, Roozbahani M (2012) Conjunctival nodule in rheumatoid arthritis. Int Ophthalmol 32:81–83
178. Khraishi MM, Singh G (1996) The role of anti-malarials in rheumatoid arthritis—the American experience. Lupus 5(Suppl 1):S41–S44
179. Kingsbury SR et al. (2013) Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial. Trials 14:64
180. Kim KA, Park JY, Lee JS, Lim S (2003) Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 26:631–637
181. Klinefelter HF, Achurra A (1973) Effect of gold salts and antimalarials on the rheumatoid factor in rheumatoid arthritis. Scand J Rheumatol 2:177–182
182. Knutson VP, Ronnett GV, Lane MD (1985) The effects of cycloheximide and chloroquine on insulin receptor metabolism. J Biol Chem 260:14180–14188
183. Köppel C, Tenczer J, Ibe K (1987) Urinary metabolism of chloroquine. Arzneim Forsch 37:208–211
184. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, Paimela L, Blafield H, Puolakka K, Mottonen T, FIN-RACo Trial Group (2004) Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 50:2072–2081
185. Krane SM, Amento EP, Goldring SR (1986) Cellular interactions in tissue breakdown in rheumatoid arthritis. Adv Inflamm Res 11:1–12
186. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW (1993) Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis 52:360–364
187. 1. Biochemistry 24:6515–6520
188. Kull FC Jr, Besterman JM (1990) Drug-induced alterations of tumour necrosis factor-mediated cytotoxicity: discrimination of early versus late stage action. J Cell Biochem 42:1–12
189. Kyburz D, Bretano F, Gay S (2006) Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like signalling. Nature Clin Pract Rheumatol 2:458–459
190. Laaksonen AL, Koskiahde V, Juva K (1974) Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol 3:103–108
191. Lafyatis R, York M, Marshak-Rothstein A (2006) Antimalarial agents: closing the gate on toll-like receptors. Arthritis Rheum 54:3068–3070
192. Lai J-H, Ho L-J, Lu K-C, Chang D-M, Shaio M-F, Han S-H (2001) Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspases cascades and is independent of Fas/Fas ligand interaction. J Immunol 166:6914–6924
193. Landewe RBM, Miltenburg AMM, Verdonk MJA, Verweij CL, Breedveld FC, Daha MR, Dijkmans BAC (1995) Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol 102:144–151
194. Leoni A (1955) Gli effetti della chlorochina sulla riposte eritematosa al fenolo nei portatori di eritematode cronico. Minerva Derm 30:410–411
195. Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM (2003) Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–442
196. Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, Kim TS, Choi JS, Jang IJ, Park JW (2009) Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother 53:1468–1475
197. Lipsky PE (1986) Natural killer cell function in rheumatoid arthritis. Clin Exp Rheumatol 4:303–305
198. Littler TR (1990) Anti-rheumatic drugs. In: Orme M (ed) Anti-rheumatic drugs. Pergamon Press, New York, pp 189–216
199. Lomater G, Gattinara M, Gerloni V, Zeni S, Fantini F (1994) Combination therapy of juvenile rheumatoid arthritis with hydroxychloroquine-gold-methotrexate: a pilot study. Acta Univ Carol Med (Praha) 40:109–112
200. Lowe JS, Turner EH (1973) The effect of adjuvant arthritis and drugs on the ability of rat plasma to inhibit the triton X-100 induced lysis of rabbit polymorphonuclear leucocyte granules. Biochem Pharmacol 22:2069–2078
201. Lullmann-Rauch R, Pods R, von Witzendorff B (1996) The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo. Toxicology 110:27–37
202. MacIntyre AC, Cutler DJ (1986) In vitro binding of chloroquine to rat muscle preparations. J Pharm Sci 75:1068–1070
203. MacIntyre AC, Cutler DJ (1988) Role of lysosomes in hepatic accumulation of chloroquine. J Pharm Sci 77:196–199
204. Mackenzie AH (1970) An appraisal of chloroquine. Arthritis Rheum 13:280–291
205. Mackenzie AH (1983a) Antimalarial drugs for rheumatoid arthritis. Am J Med 75:48–58
206. Mackenzie AH (1983b) Pharmacologic actions of 4-aminoquinoline compounds. Am J Med 75(1A):5–10
207. Mackenzie AH (1983c) Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75(1A):40–45
208. Maksymowych W, Russell AS (1987) Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 16:206–221
209. Malbica JO, Hart LG (1971) Effect of adenosine triphosphate and some anti-inflammatory agents on a purified lysosomal fraction having high acid phosphatase and labile β-glucuronidase activity. Biochem Pharmacol 20:2017–2026
210. Manku MS, Horrobin DF (1976) Chloroquine, quinacrine, procaine, quinidine and clomipramine are prostanglandin agonsist and antagonists. Prostaglandins 12:789–801
211. Marmor MF (2004) Hydroxychloroquine at the recommended dose (
212. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF, American Academy of Ophthalmology (2002) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109:1377–1382
213. Martínez-Costa L, Victoria Ibañez M, Murcia-Bello C, Epifanio I, Verdejo-Gimeno C, Beltrán-Catalán E, Marco-Ventura P (2013) Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. Can J Ophthalmol 48:400–405
214. Mary CF, Legros J (1987) Experimental study of ocular effects of hydroxychloroquine in the rat: influence of oxidiser status. Br J Clin Pract 41(Suppl 52):46–49
215. Matsuzawa Y, Hostettler KY (1980) Inhibition of lysosomal phospholipase A and phospholipase C by chloroiquine and 4,4′-bis(diethylaminoethoxy)α, β-diethyldiphenylethane. J Biol Chem 255:5190–5194
216. McCarty DJ, Carrera GF (1982) Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine. J Am Med Assn 248:1718–1723
217. McChesney EW (1983) Animal toxicity and pharmacokinetics of hydroxychloroquine sulphate. Am J Med 75(6A):11–18
218. McChesney EW, Fitch CD (1984) 4-Aminoquinolines. In: Peters W, Richards WHG (eds) Antimalarial drugs II. Springer, Berlin, pp 3–60
219. McChesney EW, Banks WF Jr, Sullivan DJ (1965) Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats. Toxicol Appl Pharmacol 7:627–636
220. McChesney EW, Conway WD, Banks WF Jr, Rogers JE, Shekosky JM (1966) Studies on the metabolism of some compounds of the 4-amino-7-chloroquinoline series. J Pharmacol Exp Ther 151:482–493
221. McChesney EW, Banks WF Jr, Fabian RJ (1967a) Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine. Toxicol Appl Pharmacol 10:501–513
222. McChesney EW, Fasco MJ, Banks WF (1967b) The metabolism of chloroquine in man after repeated oral dosage. J Pharmacol Exp Ther 158:323–331
223. McElnay JC, Sidahmed AM, D’Arcy PF, McQuade RD (1985) Chloroquine-digoxin interaction. Int J Pharm 1985:267–274
224. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: asystematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J Am Med Assn 296:1633–1644
225. McKendry RJR et al. (2001) Hydroxychloroquine (HCQ) versus acetaminophen (ACM) versus placebo (PL) in the treatment of nodal osteoarthritis (NOA) of the hands. J Rheumatol 28:1421–1421
226. McLachlan AJ, Tett SE, Cutler DJ, Day RO (1993) Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. Br J Clin Pharmacol 36:78–81
227. McLachlan AJ, Tett SE, Cutler DJ, Day RO (1994) Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. Chirality 6:360–364
228. Meller S, Gerber PA, Homey B (2008) Clinical image: blonde by prescription. Arthritis Rheum 58:2286
229. Midha KK, McKay G, Rawson MJ, Hubbard JW (1998) The impact of stereoisomerism in bioequivalence studies. J Pharm Sci 87:797–802
230. Migkos MP, Markatseli TE, Iliou C, Voulgari PV, Drosos AA (2014) Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome. J Rheumatol 41:902–908
231. Miller LC (1995) Cytokines in rheumatic diseases. Biotherapy 8:99–111
232. Minta JO, Williams MD (1986) Interactions of antirheumatic drugs with the superoxide generation system of activated human polymorphonuclear leukocytes. J Rheumatol 13:498–504
233. Miyachi Y, Yoshioka A, Imamura S, Niwa Y (1986) Antioxidant action of antimalarials. Ann Rheum Dis 45:244–248
234. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, Laasonen L, Kaipiainen-Seppanen O, Franzen P, Helve T, Koski J, Gripenberg-Gahmberg M, Myllykangas-Luosujarvi R, Leirisalo-Repo M, the FIN-RACo Trial Group (2002) FINnish Rheumatoid Arthritis Combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898
235. Muller-Peddinghaus R, Wurl M (1987) The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers. Biochem Pharmacol 36:1125–1132
236. Mullié C, Jonet A, Desgrouas C, Taudon N, Sonnet P (2012) Differences in anti-malarial activity of 4-aminoalcohol quinoline enantiomers and investigation of the presumed underlying mechanism of action. Malar J 11:65
237. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D, Furst DE (2002) Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46:1460–1469
238. Namazi MR (2009) The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine. Lupus 18:104–105
239. Nation RL, Hackett LP, Dusci LJ, Ilett KF (1984) Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol 17:368–369
240. Nayak V, Esdaile JM (1996) The efficacy of antimalarials in systemic lupus erythematosus. Lupus 5(Suppl 1):S23–S27
241. Neal TM, Vissers MC, Winterbourn CC (1987) Inhibition by nonsteroidal anti-inflammatory drugs of superoxide production and granule enzyme release by polymorphonuclear leukocytes stimulated with immune complexes or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol 36:2511–2517
242. Nebbioso M, Livani ML, Steigerwalt RD, Panetta V, Rispoli E (2011) Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction. Clin Exp Optom 94:276–283
243. Neidel J, Zeidler U (1993) Independent effects of interleukin 1 on proteoglycan synthesis and proteoglycan breakdown of bovine articular cartilage in vitro. Agents Actions 39:82–90
244. Neil HA, Perera R, Armitage JM, Farmer AJ, Mant D, Durrington PN (2008) Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract 62:1322–1331
245. Neill WA, Panayi GS, Duthie JJR (1973) Action of chloroquine phosphate in rheumatoid arthritis. 2. Chromosome damaging effect. Ann Rheum Dis 32:547–550
246. Newbold BB (1963) Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. Br J Pharmacol Chemother 21:127–136
247. Northover BJ (1977) Effect of indomethacin and related drugs on the calcium ion-dependent secretion of lysosomal and other enzymes by neutrophil polymorphonuclear leucocytes in vitro. Br J Pharmacol 59:253–259
248. Novikoff AB, Beafay H, De Duve C (1956) Electron microscopy of lysosome rich fractions from rat liver. J Biophys Biochem Cytol 25(4 Suppl):179–184
249. Obua C, Ntale M, Lundblad MS, Mahindi M, Gustafsson LL, Ogwal-Okeng JW, Anokbonggo WW, Hellgren U (2006) Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. Afr Health Sci 6:86–92
250. O’Dell JR (1998) Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis. Rheum Dis Clin North Am 24:465–477
251. O’Dell JR (1999) Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate. Clin Exp Rheumatol 17:S53–S58
252. O’Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF (2001) Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 44:2235–2241
253. O’Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, Haire C, Fernandez A (2006) Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 33:213–218
254. Oforah E, Anyogo S (2000) The contributions of various chloroquine salts to the biliary and urinary execretion of hepatic paracetamol conjugation metabolites in the rat. Drug Metabol Drug Interact 16:129–141
255. Ogunbona FA, Onyeji CO, Bolaji OO, Torimiro SE (1987) Excretion of chloroquine and desethylchloroquine in human milk. Br J Clin Pharmacol 23:473–476
256. Ohsugi Y, Gershwin ME (1984) Inhibition by various antiarthritic agents of murine splenic B cell colony formation. Immunopharmacology 7:1–7
257. Onyeji CO, Toriola TA, Ogunbona FA (1993) Lack of pharmacokinetic interaction between chloroquine and imipramine. Ther Drug Monit 15:43–46
258. Østensen M, Brown ND, Chiang PK, Aarbakke J (1985) Hydroxychloroquine in human breast milk. Eur J Clin Pharmacol 28:357
259. Padol IT, Hunt RH (2010) Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology 49:837–843
260. Page F (1951) Treatment of lupus erythematosus with mepacrine. Lancet 2:755–758
261. Panayi GS, Neill WA, Duthie JJR, McCormick JN (1973) Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect. Ann Rheum Dis 32:316
262. Pappu A, Hauser G (1981) Changes in brain phosphoinositide metabolism induced by cationic amphiphilic drugs in vitro. Biochem Pharmacol 30:3234–3246
263. Parke AL (1993) Antimalarial drugs, pregnancy and lactation. Lupus 2(Suppl 1):S21–S23
264. Pasternak RD, Marks RL, Hubbs SJ, DiPasquale G (1985) Effects of antirheumatic agents on the mitogen response of arthritic rat spleen cells. Rec Commun Chem Path Pharmacol 48:353–367
265. Paulus HE (1988) Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs. Am J Med 85:45–52
266. Pavelka K Jr, Pavelka Sen K, Peliskova Z, Vacha J, Trnavsky K (1989) Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens. Ann Rheum Dis 48:542–546
267. Payne JP (1894) A lecture on lupus erythematosus. Clin J IV:223
268. Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, Manzi S, Wasko MC (2010) Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 37:1136–1142
269. Perrin DD (1965) Dissociation constants of organic bases in aqueous solutions. Butterworths, London
270. Petri M (1996) Hydroxychloroquine use in the Baltimore Lupus Cohort; effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16–S22
271. Petri M (2005) Lupus in Baltimore: evidence-based ‘clinical pearls’ from the Hopkins Lupus Cohort. Lupus 14:970–973
272. Petri M, Purvey S, Fang H, Magder LS (2012) Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 64:4021–4028
273. Pettipher ER, Higgs GA, Henderson B (1986) Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986(83):8749–8753
274. Pico S, Peyron F, Vuillez J-P, Polack B, Ambroise-Thomas P (1991) Chloroquine inhibits tumour necrosis factor production by human macrophages in vitro. J Infect Dis 164:830
275. Pons-Estel GJ, Alarcón GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, Reveille JD, Vilá LM, Lumina Study Group (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61:830–839
276. Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, Ducharme J (2003) In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 31:748–754
277. Punzi L et al. (1996) Soluble interleukin 2 receptors and treatment with hydroxychloroquine in erosive osteoarthritis. J Rheumatol 23:1477–1478
278. Pussard E, Verdier, Blayo M-C (1986) Simultaneous determination of chloroquine, amadiaquine and their metabolites in human plasma, red blood cells, and whole blood and urine by column liquid chromatography. J Chromatogr 374:111–118
279. Raghoebar M, Peeters PA, van den Berg W, van Ginneken CA (1986) Mechanisms of cell association of chloroquine to leucocytes. J Pharmacol Exp Ther 238:302–306
280. Raina RK, Bano G, Amla V, Kapoor V, Gupta KL (1993) The effect of aspirin, paracetamol and analgin on pharmacokinetics of chloroquine. Indian J Physiol Pharmacol 37:229–231
281. Rainsford KD (1985) Effects of anti-inflammatory drugs on catabolin-induced cartilage destruction in vitro. Int J Tissue React 7:123–126
282. Rainsford KD (1986) Effects of antimalarial drugs on interleukin 1-induced cartilage proteoglycan degradation in-vitro. J Pharm Pharmacol 38:829–833
283. Rainsford KD (1987) Effects of anti-inflammatory drugs on the release from synovial tissues of cartilage-resorbing (catabolin-like) activity in vitro: role of assay conditions and drug effects on eicosanoid metabolism. In: The control of tissue damage. The Strangeways Research Laboratory 75th Annual Symposium. Arthritis and Rheumatism Council for Research, p 130
284. Rainsford KD (1988) Inhibitors of prostaglandin and leukotriene production. In: Curtis-Prior PB (ed) Prostaglandins: biology and chemistry of prostaglandins and related eicosanoids. Churchill-Livingstone, London, pp 52–68
285. Rainsford KD (1990) Analgesics vs. nonsteroidal anti-inflammatory drugs (NSAIDs): differences among NSAIDs. In: Brandt KD (ed) Cartilage changes in osteoarthritis. Indiana University School of Medicine, pp 129–136
286. Rainsford KD (1992). Effects of antimalarial drugs oin the progression of adjuvant induced arthritis in rats. Unpublished studies
287. Rainsford KD, Rashad SY, Revell PA, Low FM, Hemingway AP, Walker FS, Johnson D, Stetsko P, Ying C, Smith F (1992) Effects of NSAIDs on cartilage proteoglycan and synovial prostaglandin metabolism in relation to progression of joint deterioration in osteoarthritis. In: Bálint G, Gömör B, Hadinka L (eds) Rheumatology, state of the art. Elsevier, Amsterdam, pp 177–183
288. Rand JH, Wu X-X, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ (2008) Hydroxychloroquine directly reduces the binding of anti-phospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers. Blood 112:1687–1695
289. Räsänen L, Lehto M, Hyöty H, Leinikki P (1989) Collaboration between human blood dentritic cells and monocytes in antigen presentation. APMIS 97:981–986
290. Riches DWH, Stanworth DR (1982) Weak-base induced lysosomal secretion by macrophages: an alternative trigger mechanism that is independent of complement activation. Adv Exp Biol 155:313–323
291. Riches DWH, Morris CJ, Stanworth DR (1981) Induction of selective acid hydrolase release from mouse macrophages during exposure to chloroquine and quinine. Biochem Pharmacol 30:629–634
292. Robertson CR et al. (1993) Treatment of erosive osteoarthritis with hydroxychloroquine. Arthritis Rheum 36:S167
293. Ruiz-Irastorza G, Khamashta MA (2008) Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 17:271–273
294. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus. Ann Rheum Dis 69:20–28
295. RxFiles Detailing Program (2008) Drug comparison charts, 7th edn. In: Jensen B, Regier LD (Eds). Saskatoon City Hospital, Saskatoon, p 62
296. Rynes RI (1988) Toxicity of antimalarial drugs in rheumatoid arthritis. Agents Actions Suppl 44:151–157
297. Rynes RI (1992) Antimalarials. In: Dixon JS, Furst DE (eds) Second-line agents in the treatment of rheumatic diseases. Marcel Dekker, New York, pp 245–266
298. Rynes RI (1997) Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 36:799–805
299. Saklatvala J, Sarsfield SJ (1988) How do interleukin-1 and tumour necrosis factor induce degradation of proteoglycan in cartilage? In: Glauert A (ed) The control of tissue damage. Elsevier, Amsterdam, pp 97–108
300. Saklatvala J, Pilsworth LMC, Sarsfield SJ, Gavrilovic J, Health JK (1984) Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandins and collagen, and thymocyte proliferation is augmented in response to one protein. Biochem J 224:461–466
301. Salaffi F, Carotti M, Cervini C (1996) Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis. Scand J Rheumatol 25:16–23
302. Salmeron G, Lipsky PE (1983) Immunosuppressive potential of antimalarials. Am Med J 75(1A):19–24
303. Salton DJ (1987) Chloroquine and the eye. Br J Clin Pract 41(Suppl 52):50–55
304. Sammaritano LR, Bermas BL (2014) Rheumatoid arthritis medications and lactation. Curr Opin Rheumatol 26:354–360
305. Sams WM (1967) Chloroquine: mechanism of action. Mayo Clin Proc 42:300–309
306. Sanders M (2000) A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheumatol 27:523–529
307. Saviola G et al. (2012) Clondronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. Mod Rheumatol 22(2):256–263
308. Scala G, Oppenheim JJ (1983) Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleuklin 1. J Immunol 131:1160–1166
309. Schug BS, Kalbhen DA (1995) Influence of chloroquine and other substances on the collagenolytic activity in human osteoarthritic cartilage in vitro. Arzneimittelforschung 45:285–289
310. Semrau K, Kuhn L, Kasonde P, Sinkala M, Kankasa C, Shutes E, Vwalika C, Ghosh M, Aldrovandi G, Thea DM (2006) Impact of chloroquine on viral load in breast milk. Trop Med Int Health 11:800–833
311. Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Mariette X, Vitali C (2014) Outcome measures for primary Sjögren’s syndrome: a comprehensive review. J Autoimmun 51:51–56
312. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, Bootsma H, Tzioufas A, Solans-Laqué R, Mandl T, Gottenberg JE, Hachulla E, Sivils KL, Ng WF, Fauchais AL, Bombardieri S, Valesini G, Bartoloni E, Saraux A, Tomsic M, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Vitali C, Mariette X, Bowman SJ, Sjögren’s Task Force EULAR (2015) Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:859–866
313. Shearer RV, Dubois EL (1967) Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy. Am J Ophthalmol 64:245–252
314. Sheppeard H, Pilsworth LM, Hazleman B, Dingle JT (1982) Effects of antirheumatoid drugs on the production and action of porcine catabolin. Ann Rheum Dis 41:463–468
315. Sibtain SK et al. (2007) Role of hydroxychloroquine in management of osteoarthritis. Rheumatology (Oxford) 46:i61–i61
316. Silva MA, Ishii-Iwamoto EL, Bracht A, Caparroz-Assef SM, Kimura E, Cuman RK, Bersani-Amado CA (2005) Efficiency of combined methotrexate/chloroquine therapy in adjuvant-induced arthritis. Fundam Clin Pharmacol 19:479–489
317. Sisó A, Ramos-Casals M, Bové A, Brito-Zerón P, Soria N, Muñoz S, Testi A, Plaza J, Sentís J, Coca A (2008) Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17:281–288
318. Skinner-Adams TS, Andrews KT, Melville L, McCarthy J, Gardiner DL (2007) Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 51:759–762
319. Smith RJ (1977) Modulation of phagocytosis by and lysosomal enzyme secretion from guinea-pig neutrophils: effect of nonsteroid anti-inflammatory agents and prostaglandins. J Pharmacol Exp Ther 200:647–657
320. Sneader W (2005) Drug discovery. A history. John Wiley, Chichester
321. Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M (2000) Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 49:549–554
322. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK (1994) The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 38:15–22
323. Sperber K, Quraishi H, Kalb TH, Stecher V, Mayer L (1993) Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1α) and IL-6 in human monocytes and T cells. J Rheumatol 20:813–818
324. Stecher VJ, Connolly KM, Speicht PT (1987) Fibronectin and macrophages as parameters of disease-modifying antirheumatic activity. Br J Clin Practice 41(Suppl 52):64–71
325. Stepien KB, Wilczok T (1982) Studies on the mechanism of chloroquine binding to synthetic DOPA-melanin. Biochem Pharmacol 31:3359–3365
326. Stepien K, Porebska M, Wilczok T (1987) Interaction of chloroquine with melanosomes and model melanin complexes. Stud Biophys 122:165–174
327. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, Lindsley CB, Ota S, Pilkington C, Reed AM, Scuccimarri R, Feldman BM (2010) Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol 37:1953–1961
328. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L (2007) TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 6:223–235
329. Suzuki Y, Ito I, Ito M, Yamagami I (1973) Changes of mucopolysaccharase, protease and collagenolytic activities in rats with adjuvant arthritis and the effects of various anti-inflammatory drugs. Nippon Yakurigaku Zasshi 69:947–968 (in Japanese)
330. Tagoe CN, Ofori-Adjei D (1995) Effects of chloroquine and its enantiomers on the development of rat embryos in vitro. Teratology 52:137–142
331. Tang C, Godfrey T, Stawell R, Nikpour M (2012) Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 42:968–978
332. Tauber R, Heinze K, Reutter W (1985) Effect of chloroquine on the degradation of l-fucose and the polypeptide moiety of plasma membrane glycoproteins. Eur J Cell Biology 39:380–385
333. Tehrani R, Ostrowski RA, Hariman R, Jay WM (2008) Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 23:201–209
334. Teitz CC, Chrisman OD (1975) The effect of salicylate and chloroquine on prostaglandin-induced articular damage in the rabbit knee. Clin Orthop Relat Res 12:264–274
335. Tejeswar Rao P (1977) Intra-articular chloroquine in rheumatoid and osteo-arthritis of knee joint. J Indian Med Assoc 69(9):193–195
336. Tett SE (1993) Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 25:392–407
337. Tett SE, Cutler DJ, Day RO, Brown KF (1989) Bioavailability of hydroxychloroquine tables in healthy volunteers. Br J Pharmacol 27:771–779
338. Tett S, Cutler D, Day R (1990) Antimalarials in rheumatic diseases. Bailliere’s Clin Rheumatol 4:467–489
339. Tett S, McLachlan A, Day R, Cutler D (1993) Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine. Agents Actions Suppl 44:145–190
340. Tett SE, McLachlan AJ, Cutler DJ, Day RO (1994) Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 6:355–359
341. Thiele DL, Lipsky PE (1985a) Modulation of human natural killer cell function by l-leucine methyl ester: monocyte-dependent depletion from human peripheral blood mononuclear cells. J Immunol 134:786–793
342. Thiele DL, Lipsky PE (1985b) Regulation of cellular function by products of lysosomal enzyme activity: elimination of human natural killer cells by a dipeptide methyl ester generated from l-leucine methyl ester by monocytes or poplymorphonuclear leukocytes. Proc Nat Acad Sci USA 82:2468–2472
343. Thompson GR, Bartholomew L (1964) The effect of chloroquine on antibody production. Univ Michigan Med Ctr J 30:227–230
344. Thorens B, Vassalli P (1986) Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. Nature 321:618–620
345. Titus EO (1989) Recent developments in the understanding of the phramacokinetics and mechanism of action of chloroquine. Ther Drug Monit 11:369–379
346. Trnavská Z, Trnavský K (1967) Influence of anti-rheumatic drugs on urinary excretion of hydroxyproline in lathyrism. Nature 214:384
347. Trnavsky K, Gatterova J, Linduskova M, Peliskova Z (1993) Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis. Z Rheumatol 52:292–296
348. Tzekov R (2005) Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. Doc Ophthalmol 110:111–120
349. Van Cauwenberge H, Lecomte J, Lapiere C (1958a) Influence de la chloroquine sur l’oedeme a la ovalbumine ou au dextran, et sur la test d’ambrose et de eds chez le rat. C R Soc Biol 152:1405–1408
350. Van Cauwenberge H, Lecomte J, Lapiere C (1958b) Influence de la chloroquine sur le development du granulome a l’ouate et sur la poche granulomateuse. C R Soc Biol 152:1414–1417
351. van den Borne BE, Landewe RB, Goei The HS, Rietveld JH, Zwinderman AH, Bruyn GA, Breedveld FC, Dijkmans BA (1998) Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 25:1493–1498
352. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036–1038
353. van Loenen HJ, Dijkmans BA, De Vries E (1990) Concentration dependency of cyclosporin and chloroquine as inhibitors of cell proliferation and immunoglobulin production upon mitogen stimulation of mononuclear cells. Clin Exp Rheumatol 1990(8):59–61
354. Van Roon EN, van den Bemt PMLA, Jansen TLThA, Houtman NM, van de Laar MAFJ, Brouwers JRBJ (2009) An evidence-based assessment of the clinical significance between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clin Ther 31:1737–1746
355. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, Zickert A, Theander J, Thorner A, Hellstrom H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wornert M, Bratt J (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374:459–466
356. Varga F (1968a) Tissue distribution of chloroquine in the rat. Acta Physiol Acad Sci Hung Tomus 34:319–325
357. Varga F (1968b) Intracellular localization of chloroquine in the liver and kidney of the rat. Acta Physiol Acad Sci Hung Tomus 34:327–332
358. Vayuvegula B, Ohira K, Gollapudi S, Gupta S (1990) Role of monocytes in anti-CD3—induced T-cell DNA synthesis: effect of chloroquine and monensin on anti-CD3—induced T-cell activation. J Clin Immunol 10:247–254
359. Verstappen SM, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, Borg EJ, Hofman DM, van der Veen MJ, the Utrecht Arthritis Cohort Study Group (2003) Five-year follow-up of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 48:1797–1807
360. Vezmar M, Georges E (2000) Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol 59:1245–1252
361. Viala A, Deturmeny E, Aubert C, Estadieu M, Durnad A, Cano JP, Delmont J (1983) Determination of chloroquine and monodesethylchloroquine in hair. J Forensic Sci 28:922–928
362. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558
363. Vitali C, Bootsma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, Ramos-Casals M, Ravaud P, Seror R, Theander E, Tzioufas AG (2013) Classification criteria for Sjogren’s syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 72:476–478
364. Volastro PS, Malawista SE, Chrisman OD (1973) Chloroquine: protective and destructive effects on injured rabbit cartilage in vivo. Clin Orthop Relat Res 14:243–248
365. Vuolteenaho K, Moilanen T, Hämäläinen M, Moilanen E (2003) Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage. Role of endogenous IL-1 inhibitors. Scand J Rheumatol 32:19–24
366. Vuolteenaho K, Kujala P, Moilanen T, Moilanen E (2005) Aurothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage. Scand J Rheumatol 34:475–479
367. Wallace DJ (1996) The history of antimalarials. Lupus 5(Suppl 1):S2–S3
368. Ward PA (1966) The chemosuppression of chemotaxis. J Exp Med 23:1038–1044
369. Wei LC, Chen SN, Ho CL, Kuo YH, Ho JD (2001) Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report. Chang Gung Med J 24:329–334
370. Weissmann G (1984) Labilization and stabilization of lysosomes. Federation Proc 23:1038–1044
371. White NJ (1985) Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10:187–215
372. Whitehead RW, Hager JP (1954) The anti-inflammatory and anti-hyaluronidase effect of chloroquine diphosphate. J Pharmacol Exp Ther 110:52–53
373. Whitehouse MW (1967) Evaluation of potential antirheumatic drugs in vitro using lymphocytes and epithelial cells. The selective action of indoxole, methyl glyoxal and chloroquine. J Pharm Pharmacol 19:590–595
374. Whitehouse MW, Boström H (1962) The effect of some anti-rheumatic drugs on the metabolism of connective tissues. Biochem Pharmacol 11:1175–1201
375. Whitehouse MW, Boström H (1965) Biochemical properties of anti-inflammatory drugs. VI. The effects of chloroquine (resochin), mepacrine (quinacrine) and some of their potential metabolites on cartilage metabolism and oxidative phosphorylation. Biochem Pharmacol 14:1173–1184
376. Whitehouse MW, Cowley FK (1966) Inhibition of connective tissue proteases by antimalarials. Biochem J 98:118–120
377. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M (1994) Functional dichotomy of neutral and sphingomylinase in tumor necrosis factor signalling. Cell 78:1005
378. Wildfeuer A (1983) Action of antirheumatic drugs on the function of human leucocytes. Arzneimittelforschung 33:780–783
379. Williams WR, Davidson LAG (1983) Effects of therapeutic drugs on lymphocyte transformation. Br J Clin Pharmacol 15:83–90
380. Witiak DT, Grattan DA, Heaslip RJ, Rahwan RG (1981) Synthesis and preliminary pharmacological evaluation of asymmetric chloroquine analogues. J Med Chem 24:712–717
381. Wolfe F, Michaud K (2008) The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 58:2612–2621
382. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C (1984) Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 10:592–600
383. Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe DP, Sysa-Jedrzejowska A (2008) The influence of antimalarial treatment in IL-1β, IL-6 and TNF-α mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dematol 159:1124–1130
384. Yanagishita M, Hascall VC (1984) Metabolism of proteoglycans in rat ovarian granulosa cell culture. Multiple intracellular degradative pathways and the effects of chloroquine. J Biol Chem 259:10270–10283
385. Yasuda T (2006) Cartilage destruction by matrix degradation products. Mod Rheumatol 16:197–205
386. Yi Q, Holm G, Lefvert AK (1996) Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clin Exp Immunol 104:359–365
387. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, Dinçer F, Dziedzic K, Häuselmann HJ, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Maheu E, Martín-Mola E, Pavelka K, Punzi L, Reiter S, Sautner J, Smolen J, Verbruggen G, Zimmermann-Górska I (2007) EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:377–388
388. Zhou D, Liu Y, Xu LH, Ouyang DY, Pan H, Zhang XY, Zhao GX, He XH (2015) Chloroquine differentially modulates inflammatory cytokine expression in RAW 264.7 cells in response to inactivated Staphylococcus aureus. Inflammation 38:745–755